Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

October 4, 2016 7:00 AM EDT

Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royaltiesSarepta and Summit to share research and development costsSarepta also receives option for Latin American rights

CAMBRIDGE, Mass. and OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT) and Summit Therapeutics plc (NASDAQ: SMMT)... More